Join to View Full Profile
603 N Wilmot RdSte 151Tucson, AZ 85711
Phone+1 520-886-0206
Fax+1 520-886-0829
Dr. Manda is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 2012 - 2015
The MetroHealth System/Case Western Reserve UniversityResidency, Internal Medicine, 2005 - 2008
Gandhi Medical CollegeClass of 2002
Certifications & Licensure
AZ State Medical License 2015 - 2027
NH State Medical License Active through 2015
OH State Medical License 2005 - 2014
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Clinical Trials
- A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 1 citationsGenomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.Linlin Xu, Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan Porter
Haematologica. 2024-07-01 - 3 citationsA phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.Sudhir Manda, Bertrand M Anz 3rd, Christopher Benton, E Randolph Broun, Habte A Yimer
Hematological Oncology. 2024-05-01 - 2 citationsIn-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management.Robert M Rifkin, Saulius K Girnius, Stephen J Noga, Ruemu E Birhiray, Suman Kambhampati
Blood Cancer Journal. 2023-09-19
Abstracts/Posters
- Real-World (RW) Treatment Patterns and Patient-Related Factors Including Quality of Life (QoL), Medication Adherence, and Actigraphy in Community Patients (pts) with N...Sudhir Manda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Long-Term Proteasome Inhibitor (PI) Therapy in Community Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Transitioning from Bortezomib (Btz)-Based to Ixazo...Sudhir Manda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b StudySudhir Manda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
